Heart 6-phosphofructo-2-kinase activation by insulin requires PKB (protein kinase B), but not SGK3 (serum- and glucocorticoid-induced protein kinase 3). by Mouton, Veronique et al.
Biochem. J. (2010) 431, 267–275 (Printed in Great Britain) doi:10.1042/BJ20101089 267
Heart 6-phosphofructo-2-kinase activation by insulin requires PKB
(protein kinase B), but not SGK3 (serum- and glucocorticoid-induced
protein kinase 3)
Ve´ronique MOUTON*1, Louise TOUSSAINT*†1, Didier VERTOMMEN*, Marie-Agne`s GUEUNING*, Liliane MAISIN*,
Xavier HAVAUX‡, Cossette SANCHEZ-CANEDO‡, Luc BERTRAND‡, Franck DEQUIEDT†, Brian A. HEMMINGS§, Louis HUE* and
Mark H. RIDER*2
*Universite´ catholique de Louvain and de Duve Institute, 75 Avenue Hippocrate, B-1200 Brussels, Belgium, †Cellular and Molecular Biology Unit, FUSAGx, 13 Avenue Marechal Juin,
5030 Gembloux, Belgium, ‡Universite´ catholique de Louvain Division of Cardiology, 55 Avenue Hippocrate, CARD5550, B-1200 Brussels, Belgium, and §Friedrich Miescher Institute
for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland
On the basis of transfection experiments using a dominant-
negative approach, our previous studies suggested that PKB (pro-
tein kinase B) was not involved in heart PFK-2 (6-phosphofructo-
2-kinase) activation by insulin. Therefore we first tested whether
SGK3 (serum- and glucocorticoid-induced protein kinase 3)
might be involved in this effect. Treatment of recombinant heart
PFK-2 with [γ -32P]ATP and SGK3 in vitro led to PFK-2 activation
and phosphorylation at Ser466 and Ser483. However, in HEK-293T
cells [HEK (human embryonic kidney)-293 cells expressing the
large T-antigen of SV40 (simian virus 40)] co-transfected with
SGK3 siRNA (small interfering RNA) and heart PFK-2, insulin-
induced heart PFK-2 activation was unaffected. The involvement
of PKB in heart PFK-2 activation by insulin was re-evaluated
using different models: (i) hearts from transgenic mice with a
muscle/heart-specific mutation in the PDK1 (phosphoinositide-
dependent protein kinase 1)-substrate-docking site injected with
insulin; (ii) hearts from PKBβ-deficient mice injected
with insulin; (iii) freshly isolated rat cardiomyocytes and perfused
hearts treated with the selective Akti-1/2 PKB inhibitor prior to
insulin treatment; and (iv) HEK-293T cells co-transfected with
heart PFK-2, and PKBα/β siRNA or PKBα siRNA, incubated
with insulin. Together, the results indicated that SGK3 is not
required for insulin-induced PFK-2 activation and that this effect
is likely mediated by PKBα.
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fructo-2-kinase (PFK-2), serum- and glucocorticoid-induced
protein kinase 3 (SGK3), small interfering RNA (siRNA).
INTRODUCTION
Insulin stimulates heart glycolysis via the recruitment of
GLUT4 (glucose transporter 4) transporters to the plasma
membrane [1,2] and activation of PFK-2 (6-phosphofructo-2-
kinase) [3]. The subsequent rise in Fru-2,6-P2 (fructose 2,
6-bisphosphate) allosterically stimulates PFK-1 (6-phospho-
fructo-1-kinase) and hence glycolysis. Insulin action involves
PI3K (phosphoinositide 3-kinase) activation [4], which generates
PIP3 (phosphatidylinositol-3,4,5-trisphosphate) in the plasma
membrane. PIP3 is a lipid second messenger, which
recruits two serine/threonine protein kinases, namely PDK1
(phosphoinositide-dependent protein kinase 1) and PKB
(protein kinase B), to the plasma membrane via their PH
(pleckstrin homology) domains. Full activation of PKB requires
phosphorylation of Thr308 by PDK1 [5,6] and phosphorylation
at a second site, Ser473 in the hydrophobic motif, by PDK2.
There is now strong evidence to suggest that the physiological
PDK2 is the mTOR (mammalian target of rapamycin)–Rictor
(rapamycin-insensitive companion of mTOR) complex TORC2
(mTOR complex 2) [7–10].
PKB exists as three isoenzymes (PKBα, β and γ , also known
as Akt1, 2 and 3 respectively) and is considered to mediate most,
if not all, short-term metabolic effects of insulin [11]. PKBα
is expressed ubiquitously, PKBβ is highly expressed in insulin-
responsive tissues, such as adipose tissue, liver and skeletal
muscle, whereas PKBγ expression is predominant in the brain.
Deletion of PKBα in mice does not affect glucose metabolism
[12–14], whereas knockout of PKBβ causes a diabetes mellitus-
type syndrome [15,16], implicating PKBβ in the control of
glucose transport by insulin. siRNA (small interfering RNA)-
directed gene silencing of PKBβ is also known to impair insulin-
stimulated glucose transport in 3T3-L1 adipocytes [17,18]. In
addition, in these cells, pharmacological PKB inhibition with
Akti-1/2, a selective inhibitor of PKBα and PKBβ, ablated
insulin-induced glucose uptake [19].
PKBα activates heart PFK-2 in vitro by phosphorylating Ser466
and Ser483 leading to a 2-fold increase in Vmax [20]. In isolated
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cardiomyocytes, the insulin-induced activation of PFK-2 was
insensitive to rapamycin and PD98059, which inhibit p70S6K
(p70 ribosomal S6 kinase) and MAPK (mitogen-activated protein
kinase) activation respectively, but was blocked by the PI3K
inhibitors wortmannin and LY294002 [21]. In addition in hearts
of muscle-specific PDK1-knockout mice, insulin failed to activate
PKB, p70S6K and PFK-2 [22], consistent with the PI3K/PDK1 axis
mediating these processes.
Our previous studies indicated that PKB was not essential
for insulin-induced heart PFK-2 activation on the basis of
co-transfection of a kinase-inactive dominant-negative PKB
construct in HEK (human embryonic kidney)-293 cells [23].
However, in a later study in HeLa cells co-transfected with active
PKB and HA (haemagglutinin)-tagged PFK-2, and stimulated
with IGF1 (insulin-like growth factor 1), PFK-2 was reported to
be phosphorylated [24]. We purified WISK (wortmannin-sensitive
and insulin-stimulated protein kinase), which phosphorylated and
activated heart PFK-2 [25]. PKB isoforms were undetectable in
the WISK preparation by immunoblotting, and although PKC
(protein kinase C) ζ was present, it is unlikely that this insulin-
stimulated AGC-type kinase (protein kinase A/protein kinase
G/protein kinase C-family kinases) is required for heart PFK-2
activation [26]. The SGKs (serum- and glucocorticoid-induced
protein kinases) are three serine/threonine AGC-type kinases
homologous with PKB, which are also potential candidates for
insulin-induced heart PFK-2 activation, lying downstream of
PDK1 and activated by T-loop phosphorylation [27]. One major
structural difference between PKBs and SGKs is the absence of a
PH domain, which at the N-terminus of SGK3, but not in SGK1/2,
is replaced by a PX (Phox homology) domain [28,29] that binds
PI(3)P (phosphatidylinositol 3-phosphate) [30]. SGK3, but not
SGK1 or SGK2, is expressed in heart [28] and has a molecular
mass compatible with that of WISK [25,26].
In the present study we re-investigated heart PFK-2 activation
by insulin. We first tested whether SGK3 is a PFK-2 kinase
and whether its activation in heart by insulin was required for
PFK-2 activation. Given the inherent drawbacks of the PKB
dominant-negative approach, we re-evaluated insulin-induced
PFK-2 activation in four different systems: (i) hearts from
transgenic mice with a muscle/heart-specific mutation in the
PDK1-substrate-docking site injected with insulin; (ii) hearts from
PKBβ-deficient mice injected with insulin; (iii) freshly isolated
rat cardiomyocytes and perfused hearts treated with Akti-1/2 prior
to insulin treatment; and (iv) HEK-293T [HEK-293 cells ex-
pressing the large T-antigen of SV40 (simian virus 40)] cells
co-transfected with heart PFK-2, and PKBα/β siRNA or PKBα
siRNA and incubated with insulin. The results indicate that SGK3
is not essential for heart PFK-2 activation by insulin and that this
effect is likely to be mediated by PKBα.
EXPERIMENTAL
Materials
Radiochemicals and other reagents were from sources described
previously [26]. The Akti-1/2 PKB inhibitor VIII was from
Calbiochem. Active PKBα [31], the wild-type SGK3-expressing
plasmid (pEBG2t-GST-SGK3) [28], the anti-total SGK3 [28] and
anti-total PKBβ and PKBγ [32] antibodies were a gift from
Professor Dario Alessi (Department of Biochemistry, University
of Dundee, Dundee, U.K.). A polyclonal anti-phospho-Thr320
SGK3 antibody was raised against the phosphorylated peptide
C-AISDTTTTpFCG (residues 313–323 of human SGK3 contain-
ing the activation loop phosphorylated Thr320 plus an N-terminal
cysteine residue for coupling to keyhole limpet haemocyanin
with 3-maleimidobenzoic acid N-hydroxysuccinimide ester)
by immunization in sheep. The phosphorylated and non-
phosphorylated C-AISDTTTTFCG peptides (10 mg of each)
were coupled to 2 ml of thiol–Sepharose suspension (from 1.4 g
of dried gel swollen in 5 ml of water) in coupling buffer
(0.1 M Tris/HCl, pH 7.5, 1 mM EDTA and 0.3 M NaCl) for
2 h with rotation at room temperature (25 ◦C). The resins were
washed three times with coupling buffer (with centrifugation at
1500 g for 20 s to collect the gel), twice with 0.1 M sodium
citrate, pH 4.5, and were then resuspended in 0.1 M
sodium citrate, pH 4.5, containing 1 mM 2-mercaptoethanol,
followed by incubation for 90 min at room temperature. The
resins were extensively washed with PBST (PBS containing
0.1% Tween 20). Aliquots of serum (16 ml) were then incubated
with gel containing the immobilized non-phosphorylated peptide
(overnight at 4 ◦C) before applying the supernatant to a column
containing the immobilized phosphopeptide. After extensive
washing with PBST, anti-phospho antibodies were eluted with ad-
ditions of 1 ml of 100 mM glycine and collected in tubes contain-
ing 40 μl of 1 M Tris base. The eluted protein fractions were com-
bined, concentrated by ultrafiltration and dialysed against PBS for
storage in aliquots at − 20 ◦C. The anti-total PFK-2 antibody was
raised against full-length purified recombinant BH (bovine heart)
PFK-2 (see below) in rabbits; anti-PAS (phospho-Akt substrate)
and anti-phospho-Ser473 PKB antibodies were from Cell Signaling
Technology; anti-PH domain PKB and anti-PKBα antibodies
were from Upstate Biotechnology; and anti-total p70S6K antibody
was from Santa Cruz Biotechnology. The shRNA (small hairpin
RNA) plasmid vectors encoding mammalian PKBα siRNA [pKD-
AKT1/PKBα-v2], mammalian negative control siRNA [pKD-
NegCon-v1], mammalian SGK3 siRNA [pKD-SGK3-v1] and
Akt siRNA double-stranded RNAs, which targets both PKBα
and PKBβ isoforms, and the corresponding control siRNAs were
from Cell Signaling Technology. For the p70S6K, SGK3 and PKB
assays, the substrate peptides were KKRNRTLSVA (derived from
ribosomal protein S6), PVRMRRNSFT (a peptide containing
Ser466 of heart PFK-2) and RPRAATF [33] respectively
(the phosphorylated residue is underlined) and were kindly
synthesized by V. Stroobant (Ludwig Institute for Cancer
Research, Brussels, Belgium). The purified recombinant His6-
tagged BH1 PFK-2 isoform [23] and recombinant activated
GST (glutathione transferase)–SGK3 [28] from HEK-293 cells
incubated with insulin were produced as described previously.
Culture and transfection of HEK-293T cells
HEK-293T cells were cultured in 10-cm-diameter dishes in
DMEM (Dulbecco’s minimal essential medium) containing 10%
(w/v) fetal bovine serum. They were transfected on the following
day by the JetPEI procedure according to the manufacturer’s
instructions (PolyPlus Transfection). Cells were transfected with
wild-type BH PFK-2 (0.5 μg of BH1–His6), 5 μg of PKBα
shRNA plasmid vector, 5 μg of negative control shRNA plasmid
vector, 5 μg of SGK3 shRNA plasmid vector, empty vector
(5 μg of PCMV5), 50 nM Akt siRNA and/or 50 nM control
siRNA as indicated. Transfection was performed at 37 ◦C in
DMEM containing 10% (w/v) fetal bovine serum. After 32 h
(for protein overexpression), 48 h (for PKB α/β silencing with
Akt siRNA), 56 h (for SGK3 silencing with shRNA vector) or
96 h (for PKBα silencing with shRNA vector), the cells were
deprived of serum in DMEM for at least 3 h and then incubated
with or without 0.1 μM insulin for 10 min. Cells were lysed
in 600 μl of ice-cold Buffer A (50 mM Hepes, pH 7.5, 50 mM
potassium fluoride, 1 mM potassium phosphate, 1 mM EDTA,
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1 mM EGTA, 1 μM microcystin, 1 mM Na3VO4, 0.1% (v/v)
2-mercaptoethanol, 1 mM PMSF, 1 mM benzamidine hydrochlor-
ide and 1 μg/ml leupeptin) and stored at − 80 ◦C.
Rat heart perfusion and incubation of isolated cardiomyocytes
All animal experimentation was approved by the Ethical
Committee of the Faculty of Medicine, Universite´ catholique
de Louvain. Hearts from fed male Wistar rats were perfused by
the Langendorff method in Krebs–Henseleit bicarbonate buffer
containing 5 mM glucose, and 1 μM Akti-1/2 or DMSO vehicle,
for 15 min prior to perfusion with or without 0.1 μM insulin
for 10 min [25]. Hearts were freeze-clamped and homogenized
in 4 volumes of buffer containing 50 mM Hepes, pH 7.5, 0.2 M
sucrose, 1 mM EDTA, 1 mM EGTA, 20 mM sodium fluoride,
5 mM sodium pyrophosphate, 5 mM sodium 2-glycerophosphate,
15 mM 2-mercaptoethanol, 2 mM benzamidine hydrochloride,
1 μg/ml leupeptin, 1 μg/ml aprotinin and 0.2 mM PMSF using
an Ultra-Turrax homogenizer (three times for 15 s on ice).
Homogenates were centrifuged at 24000 g for 30 min. Isolated
cardiomyocytes were prepared [21] and pre-incubated with
10 μM Akti-1/2 inhibitor or DMSO vehicle for 15 min prior
to treatment with or without 0.1 μM insulin for 5 min. For Fru-
2,6-P2 measurement the cells were placed in hot alkali [21]. For
enzyme assays the cells were extracted in buffer [1 ml for 60 mg
of cells (wet weight)] containing 20 mM Hepes, pH 7.5, 100 mM
KCl, 1 mM EDTA, 20 mM sodium floride, 1 mM dithiothreitol,
1 mM PMSF, and 0.1 mM fructose 6-phosphate/0.3 mM glucose
6-phosphate using an Ultra-Turrax homogenizer (three times for
20 s on ice). Following centrifugation as described above, the
supernatants were removed and stored frozen at − 80 ◦C for
subsequent enzyme assay and immunoblotting.
Insulin administration to control and transgenic mice
Wild-type, PKBβ − /− , PDK1fl/L155EMckCre− /− and PDK1fl/L155E-
MckCre+/− (where Mck is muscle creatine kinase) mice
were starved overnight and anaesthetized (20 mg/kg of body
weight Rompun and 100 mg/kg of body weight Imalgene
intraperitoneally) prior to the intravenous injection of insulin (1
m-unit/kg of body weight) via the vena cava. At the indicated
times, hearts were freeze-clamped between tongs pre-cooled
in liquid nitrogen and homogenized in 4 volumes of buffer
containing 20 mM Hepes, pH 7.6, 30 mM KCl, 20 mM sodium
floride, 1 mM EDTA, 1 mM dithiothreitol, 1 μg/ml leupeptin,
1 μg/ml aprotinin, 0.1 mM PMSF and 0.1 mM fructose 6-
phosphate/0.3 mM glucose 6-phosphate. Extracts were prepared
as described above for Fru-2,6-P2 measurement, the PFK-2, PKB
and p70S6K assays, and immunoblotting (see below).
Measurement of Fru-2,6-P2 content and enzyme assay
Fru-2,6-P2 content and LDH (lactate dehydrogenase) activity
were measured as described previously [3]. PFK-2 activity
was measured in 5–20% PEG [poly(ethylene glycol)] 8000
fractions of extracts from cardiomyocytes or HEK-293T cells
overexpressing heart PFK-2 as described previously [3,26]. PKB
and p70S6K [34] were assayed following immunoprecipitation of
200 μg of extract protein with 0.5 μg of anti-PH domain PKB
antibody or 1 μg of anti-p70S6K antibody pre-bound to 20 μl
of a 1:1 slurry of Protein G–Sepharose in a final volume of
50 μl of phosphorylation buffer [20] supplemented with 2.5 μM
cAMP-dependent protein kinase inhibitor peptide, 40 μM PKB
substrate peptide or 200 μM p70S6K substrate peptide, and 0.1 mM
[γ -32P]ATP (1000 c.p.m./pmol). After 20 min at 30 ◦C, 15
μl aliquots were taken and spotted on to Whatman P81
phosphocellulose papers and plunged into ice-cold 75 mM
phosphoric acid. After extensive washing, 32P incorporation was
measured by liquid scintillation counting. One unit of enzyme
activity corresponds to the formation of 1 μmol (PFK-2 or LDH)
or 1 nmol (protein kinase) of product per min under the assay
conditions.
Immunoblotting
For HEK-293T cells, extracts (30 μg of protein for PKB and
SGK3 detection; 5 μg of protein for PFK-2 detection) were
subjected to SDS/PAGE (10% gels). Proteins were electro-
eluted on to PVDF membranes, which were probed with primary
antibodies. Immunoreactive bands were detected by enhanced
chemiluminescence after incubation with a secondary peroxidase-
coupled antibody. For immunodetection of SGK3 in hearts
from control/PDK-1-knockin mice or perfused rat hearts, 100–
130 μg of extracts were loaded on to 10% (w/v) acrylamide or
7.5% (w/v) acrylamide pre-cast gels respectively, for SDS/PAGE,
electro-elution [blocking of PVDF membranes was with 5%
(w/v) BSA in Tris-buffered saline containing 0.1% Tween 20].
Membranes were probed with the anti-phospho-Thr320 SGK3
antibody (1:100 dilution for a first purification of antibody on
extracts from control/PDK-1-knockin mice and 1:1000 dilution
of a second purification of antibody on extracts from perfused
hearts) or the anti-total SGK3 antibody (1:500 or 1:800 dilution
respectively). Immunoreactive bands were detected by enhanced
chemiluminescence (Pierce) after incubation with a secondary
peroxidase-coupled anti-sheep antibody used at 1:10000 and
1:80000 dilution respectively.
In vitro phosphorylation of recombinant bovine heart PFK-2
Recombinant heart PFK-2 (2 μg) was incubated with activated
GST–SGK3 (12 m-units) purified from insulin-stimulated
transfected HEK-293T cells (see above) and 0.1 mM [γ -32P]ATP
(1000 c.p.m./pmol) in a final volume of 100 μl of phosphorylation
buffer [20]. At various times, 15 μl aliquots were taken for
SDS/PAGE (10% acrylamide mini-gels). The stoichiometry of
32P incorporation was calculated as described previously [26].
To measure the effects of phosphorylation on PFK-2 activity,
1 μg of recombinant heart enzyme was incubated with 12 m-units
of PKB or 10 m-units of SGK3 in a final volume of 20 μl of
phosphorylation buffer [20] and 1 mM Mg-ATP at 30 ◦C, prior to
dilution for the PFK-2 assay [26].
Phosphorylation site identification by MS
Recombinant heart PFK-2 (5 μg) was incubated as described
above with 50 m-units of SGK3 and 0.1 mM [γ -32P]ATP (specific
radioactivity 2000 c.p.m./pmol) for 60 min at 30 ◦C. After
SDS/PAGE, bands corresponding to phosphorylated PFK-2 were
excised from the gel and digested with trypsin [35]. Peptides
were separated by reverse-phase narrow-bore HPLC at a flow rate
of 200 μl/min, and radioactive peaks were detected by Cerenkov
counting and analysed by nano-ESI (electrospray ionization)
tandem MS in a LCQ Deca XP Plus ion-trap mass spectrometer
(ThermoScientific).
Other methods
Protein concentration was estimated [36] with γ -globulin as a
standard. PFK-2 activities were expressed as specific activities
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(per unit of LDH to correct for differences in homogenization and
recovery or as arbitrary units in transfected HEK-293T cells) after
correcting specific activities for PFK-2 content as measured by
immunoblotting PEG fractions with the anti-BH PFK-2 antibody
and quantification of blots by scanning densitometry. The results
are expressed as the means +− S.E.M. for the indicated number of
individual experiments. The statistical significance of the results
was assessed by a two-sided unpaired or paired Student’s t test
as indicated. Band intensities of immunoblots were quantified
by scanning films and processing the image intensities with the
program Image J (version 1.33 for Mac OS X).
RESULTS
Role of SGK3 in heart PFK-2 activation by insulin
In HEK-293T cells transfected with a plasmid encoding full-
length SGK3 fused to GST (GST–SGK3), 0.1 μM insulin
led to a 2-fold activation of SGK3 after 5 min and to a
parallel increase in the phosphorylation state of the activation
loop Thr320 residue of SGK3 (Supplementary Figure S1
at http://www.BiochemJ.org/bj/431/bj4310267add.htm). Recom-
binant GST–SGK3 purified from insulin-treated HEK-293T
cells phosphorylated BH PFK-2 in a time-dependent manner
(Figure 1A). The stoichiometry of phosphorylation tended
towards 0.9 mol of phosphate incorporated/mol of subunit protein
after 40 min of incubation, which is close to the stoichiometry
(0.8, mol/mol) obtained with PKB [25]. Phosphorylation of
heart PFK-2 by SGK3 or PKB increased the Vmax of PFK-2 2-
fold (Figure 1B). For phosphorylation site identification by MS,
heart PFK-2 was maximally phosphorylated by activated GST–
SGK3, digested with trypsin and the radioactive peptides were
separated by HPLC (Figure 1C). The first peak contained a peptide
(N465SFTPLSSSNTIR477) in which Ser466 (underlined) was
phosphorylated, as determined by tandem MS, whereas the second
peak contained a peptide (N481YSVGSRPLQPLSPLR496) in which
Ser483 (underlined) was phosphorylated. These phosphorylation
sites are identical with the in vitro sites for PKB [25,26] and with
those identified in intact HEK-293 cells transfected with heart
PFK-2 and incubated with insulin [23].
As cultured cardiomyocytes are difficult to transfect efficiently,
we investigated the role of SGK3 in insulin-induced heart PFK-2
activation in transfected HEK-293 cells. These cells do not express
insulin receptors, but do have IGF1 receptors that bind insulin,
and contain all the elements of the insulin signalling pathway.
Although HEK-293 cells have successfully been used by others
[37] and ourselves [23] to study insulin signalling downstream
of PDK1, these cells do not express a functional metabolic end-
point for insulin, and the stoichiometry and expression of insulin
signalling components might not be similar to those of primary
cells that are physiological targets for insulin. HEK-293T cells
were co-transfected with heart PFK-2 and with a plasmid coding
for SGK3 siRNA, prior to insulin treatment. Immunoblotting
with anti-total SGK3 antibody revealed that SGK3 levels were
decreased by at least 80% in cells transfected by SGK3 siRNA
(Figure 2A). In non-transfected cells, immunoblotting with anti-
phospho-Thr320 SGK3 antibody revealed a 25-fold increase in
band intensity in response to insulin treatment (results not shown).
In addition, insulin activated endogenous immunoprecipitated
PKB (Figure 2B) and p70S6K (Figure 2C) both in cells transfected
with heart PFK-2 and in cells co-transfected with heart PFK-
2 and siRNA SGK3. Thus there was no effect of SGK3
siRNA transfection on insulin-induced PKB and p70S6K activation.
Moreover, co-transfection of SGK3 siRNA failed to prevent
insulin-induced activation of transfected PFK-2 (Figure 2D).
Figure 1 Phosphorylation and activation of heart PFK-2 by SGK3 in vitro
(A) Recombinant heart PFK-2 was incubated with activated SGK3 as described in the
Experimental section. At the indicated times, 32P incorporation (results are means +− S.E.M.
for three separate experiments) was measured by phosphoimaging after SDS/PAGE. (B) PFK-2
activity was measured under V max conditions (results are means +− S.E.M. for three separate
experiments) after phosphorylation of heart PFK-2 with SGK3 or PKB as described in the
Experimental section. *P < 0.05 compared with the control (paired t test). (C) Recombinant
heart PFK-2 was incubated with SGK3 and 0.1 mM [γ -32P]ATP for SDS/PAGE and in-gel trypsin
digestion. Peptides were separated by reverse-phase narrow-bore HPLC and eluting fractions
were collected and the radiation measured. The major radiolabelled peaks were analysed by
tandem MS to identify the phosphorylation sites.
These experiments suggest that SGK3 is not required for insulin-
induced heart PFK-2 activation.
Effect of insulin on PFK-2 activation in hearts of transgenic mice
bearing a muscle-specific mutation in the PDK1-substrate-docking
site
In order to further elucidate which kinase downstream of PDK1
could be involved in insulin-induced PFK-2 activation, we took
advantage of a conditional knockin mouse model in which muscle
and heart PDK1 harboured a mutation of the key residue Leu155
to glutamate in the so-called PIF pocket responsible for binding
its downstream targets [38]. Following phosphorylation of the
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Figure 2 Effect of SGK3 knockdown by siRNA on insulin-induced PFK-2
activation in transfected HEK-293T cells
(A) HEK-293T cells were co-transfected with vectors (see the Experimental section) as indicated.
Cell extracts were immunoblotted with the anti-total SGK3 and anti-total PKCζ (as a loading
control) antibodies. Following scanning densitometry, band intensities obtained with the
anti-total SGK3 antibody were calculated relative to band intensities obtained for the loading
control (a represent gel is shown in the lower panel). Following transfection, the cells were
incubated with (black bars) or without (white bars) 0.1 μM insulin for 10 min. *P < 0.05 for
the effect of transfection of SGK3 siRNA compared with the control (paired t -test) (B) PKB and
(C) p70S6K activities were measured in immunoprecipitates of cell lysates. (D) PFK-2 activities
were measured in cell extracts under V max conditions and expressed as arbitrary units, after
correction for PFK-2 expression levels, by immunoblotting as described in the Experimental
section. The results are means +− S.E.M. for three separate experiments. *P < 0.05 for the effect
of insulin compared with the control (paired t test).
hydrophobic motif serine/threonine residue of SGK1, and p70S6K
and p90RSK (p90 ribosomal S6 kinase) by PDK2, the PIF pocket
of PDK1 binds to the phosphorylated residue in the hydrophobic
motif, which then allows PDK1 to activate the downstream
kinase by phosphorylating its activation loop threonine residue.
Mutation of Leu155 to glutamate prevents SGK1, p70S6K and
p90RSK activation by insulin, but not PKB, which is activated
by an alternative mechanism. The PKB PH domain binds PIP3
thereby inducing a conformational change allowing PDK1 to
phosphorylate its activation loop Thr308 residue. Mice were
obtained in which the wild-type PDK1 allele had been flanked
with LoxP sites (PDK1fl/fl) and bred with PDK1L155E/+-knockin
mice to generate PDK1fl/L155E animals, which were in turn crossed
with transgenic mice expressing the Cre recombinase under the
Mck promoter (which induces expression of the Cre recombinase
specifically in skeletal muscle and heart) [38]. In the resulting
PDK1fl/L155EMckCre+/− mice, PDK1 expression was ablated and
expression of PDK1 only occurred from the L155E knockin allele
not flanked with LoxP sites. Intravenous injection of insulin to
control PDK1fl/L155EMckCre− /− mice activated PKB more than
5-fold after 5 min (Figure 3A) and activated p70S6K almost 13-fold
after 20 min (Figure 3B). In hearts from mice bearing the PIF-
pocket mutation (PDK1fl/L155EMckCre+/− ), PKB was activated
4-fold by insulin after 5 min (Figure 3A), whereas p70S6K activa-
tion by insulin was completely ablated (Figure 3B). In heart ex-
tracts from PDK1fl/L155EMckCre− /− and PDK1fl/L155EMckCre+/−
Figure 3 Effect of insulin on the activities of PKB, p70S6K and PFK-2, and
the effect on Fru-2,6-P2 content and SGK3 Thr320 phosphorylation in hearts of
transgenic mice bearing a muscle-specific mutation in the PDK1-substrate-
docking site
PDK1fl/L155EMckCre− /− (control, white symbols) mice and PDK1fl/L155EMckCre+/− (knockin,
black symbols) mice bearing the PIF-pocket mutation were starved for 16 h prior to intravenous
injection with insulin. At the indicated times, the hearts were rapidly excised and freeze-clamped.
(A) PKB and (B) p70S6K were immunoprecipitated from extracts and assayed by phosphorylation
of synthetic peptides. *P < 0.05 for the effect effect of insulin on p70S6K activity in heart extracts
from control mice compared with extracts from knockin mice (unpaired t test). Extracts were
also prepared for the (C) PFK-2 assay and (D) Fru-2,6-P2 measurement. The results are the
means +− S.E.M. of measurements on at least four different animals. (E) Heart extracts from
control PDK1fl/L155EMckCre− /− (white bars) and PDK1fl/L155EMckCre+/− knockin mice (black
bars) after 0 and 10 min of treatment with insulin were blotted with the anti-phospho-Thr320 and
anti-total SGK3 (loading control) antibodies (a representative blot is shown in the right-hand
panel). Following scanning densitometry, band intensities obtained with the anti-phospho -Thr320
SGK3 antibody were expressed relative to band intensities of the loading control (left-hand panel).
*P < 0.05 for the effect of insulin on SGK3 Thr320 phosphorylation compared with the 0 min
values (unpaired t test). The results are means +− S.E.M. of measurements on three different
animals.
mice, the insulin-induced increase in GSK3β Ser9 phosphoryla-
tion was comparable (results not shown), indicating that the PDK1
PIF-pocket mutation did not affect the phosphorylation of PKB
targets. Indeed, the time courses of PFK-2 (Figure 3C) activation
and the subsequent rise in Fru-2,6-P2 (Figure 3D) were similar in
hearts from PDK1fl/L155EMckCre− /− and PDK1fl/L155EMckCre+/−
mice. In contrast, the increase in SGK3 activation loop Thr320
phosphorylation in control PDK1fl/L155EMckCre− /− mice seen
10 min after insulin injection was completely abrogated in
PDK1fl/L155EMckCre+/− mice harbouring the PIF-pocket mutation
(Figure 3E). Together these findings suggest that kinases
downstream of PDK1, other than PKB and containing a
hydrophobic phosphorylation site motif, such as SGK3, are not
necessary for insulin-induced PFK-2 activation. The results also
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Figure 4 Effect of insulin on PKB and PFK-2 activity and Fru-2,6-P2 content
in hearts of PKBβ-deficient mice
Wild-type (PKBβ+/+) and PKBβ-deficient (PKBβ − /− ) mice were starved for 16 h prior to
intravenous injection of insulin (black bars) or were untreated (white bars). After 10 min, the
hearts were rapidly excised and freeze-clamped. (A) Extracts were immunoprecipitated for PKB
assay, immunoblotted with anti-PKBβ antibody [(B) shows a representative blots from three
wild-type and three PKBβ − /− mice] and also assayed for (C) PFK-2 or (D) Fru-2,6-P2 content.
The results are the means +− S.E.M. of measurements on at least four different animals. *P <
0.05 for the effect of insulin compared with the controls (unpaired t test). ∗∗P < 0.05 for the
effect of insulin in PKBβ − /− mice compared with wild-type mice (unpaired t test).
indicate that, as for SGK1, insulin-induced SGK3 activation by
PDK1 is PIF-pocket dependent and further argue against the
participation of SGK3 in heart PFK-2 activation by insulin.
Effect of insulin on PFK-2 activation in hearts of PKBβ-deficient
mice
The studies on insulin-induced PFK-2 activation in hearts from
mice bearing the PIF-pocket mutation strongly suggests that PKB,
and not SGK3, is mediating the effect of insulin. Therefore we
examined PFK-2 activation by insulin in hearts from PKBβ-
deficient mice. These mice are viable, but insulin-resistant,
whereas mice deficient in PKBα have growth defects, dying
not long after birth and so cannot be studied for insulin-induced
heart PFK-2 activation. Following intravenous injection of insulin
to anaesthetized wild-type and PKBβ-deficient mice, the hearts
were freeze-clamped and cell extracts were obtained for PKB
activity measurement after immunoprecipitation with the anti-
PH-domain PKB antibody (which recognizes PKBα and PKBβ).
Insulin induced a 3-fold activation of PKB in hearts from wild-
type mice but surprisingly, in hearts from PKBβ-deficient mice,
a 7-fold activation of PKB by insulin was seen (Figure 4A). This
increase in PKB activity in hearts from the knockout mice suggests
that the deletion of PKBβ results in over-compensation by PKBα.
The absence of PKBβ in heart extracts from PKBβ-deficient
mice was apparent after immunoblotting with the isoenzyme-
specific antibody (Figure 4B). However, owing to the fact that the
available anti-PKBα antibody was not specific and cross-reacts
Figure 5 Effect of insulin on PKB and PFK-2 activity, and Fru-2,6-P2 content
in rat cardiomyocytes treated with Akti-1/2 PKB inhibitor
Freshly isolated rat cardiomyocytes were pre-incubated with 10 μM Akti-1/2 inhibitor or DMSO
vehicle for 15 min prior to treatment with (black bars) or without (white bars) insulin (0.1 μM)
for 5 min. (A) Extracts were immunoprecipitated for the PKB assay, (B) immunoblotted with
the anti-phospho-Ser473 PKB and anti-β-actin (loading control) antibody (a representative blot
is shown), and assayed for (C) Fru-2,6-P2 content and (D) PFK-2 activity. The results are the
means +− S.E.M. of measurements on four different cell preparations. *P < 0.05 for the effect
of insulin compared with the controls (paired t test). ∗∗P < 0.05 for the effect of insulin in cells
treated with Akti-1/2 compared with control incubations (paired t test).
with PKBβ, we could not test for over-compensation by PKBα
either by immunoblotting or by the immunoprecipitation/PKB
assay. In parallel with the rise in insulin-induced PKB activity in
hearts from PKBβ-deficient mice, the increase in PFK-2 activity
(Figure 4C) and Fru-2,6-P2 content (Figure 4D) was greater in
hearts from PKBβ-deficient mice. This correlation supports the
implication that PKB mediates insulin-induced heart activation
and indicates that this effect is not mediated by PKBβ.
Effect of insulin on PFK-2 activation in rat cardiomyocytes treated
with the Akti-1/2 inhibitor
Cultured cardiomyocytes are difficult to transfect for PKB isoform
expression knockdown by RNA interference. Therefore freshly
isolated rat cardiomyocytes were pre-incubated with or without
the highly selective Akti-1/2 inhibitor, then with or without insu-
lin. We first verified that any stress induced by treatment with
the inhibitor had no effect on the activation of the AMP-activated
protein kinase, which like PKB also phosphorylates and activates
heart PFK-2 [39]. Acetyl-CoA carboxylase-2 phosphorylation,
measured by immunoblotting, was used as a surrogate marker
of AMP-activated protein kinase activation and was found to
be unaffected by pre-incubation with the Akti-1/2 inhibitor
(results not shown). Insulin treatment activated PKB approx.
4-fold after immunoprecipitation from cardiomyocyte extracts,
the effect being drastically reduced by pre-incubation with the
Akti-1/2 inhibitor (Figure 5A). Likewise, immunoblotting
revealed that the Akt-1/2 inhibitor blocked insulin-induced
PKB Ser473 phosphorylation (Figure 5B). Moreover, the insulin-
induced rise in Fru-2,6-P2 (Figure 5C) and PFK-2 activation
(Figure 5D) were abrogated in cardiomyocytes pre-incubated
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Figure 6 Effect of insulin on PKB activity and SGK3 Thr320 phosphorylation
in rat hearts perfused with Akti-1/2 PKB inhibitor
Rat hearts were perfused with 5 mM glucose, and DMSO vehicle or 10 μM Akti-1/2 inhibitor
for 15 min prior to perfusion with (black bars) or without (white bars) 0.1 μM insulin for
10 min then freeze-clamped and homogenized. (A) Extracts were immunprecipitated for the PKB
assay or (B) immunoblotted with anti-phospho-Thr320 and anti-total SGK3 (loading control)
antibodies (a representative blot is shown in the lower panel). Following scanning densitometry,
band intensities obtained with the anti-phospho-Thr320 SGK3 antibody were expressed relative
to band intensities of the loading controls (upper panel). The results are the means +− S.E.M.
for four separate experiments. *P < 0.05 for the effect of insulin compared with the controls
(unpaired t test). ∗∗P < 0.05 for the effect of insulin in hearts treated with Akti-1/2 compared
with the controls (unpaired t test).
with Akti-1/2, suggesting that PKB is involved in heart PFK-2
activation.
Intact rat hearts were perfused with Akti-1/2 to assess the effect
of the compound on the activation state of PKB and SGK3 in
response to insulin. As in cardiomyocytes (Figure 5A), insulin
induced a robust (6-fold) activation of PKB in perfused hearts,
which was markedly decreased by pre-treatment with Akti-1/2
(Figure 6A). As observed in control PDK1fl/L155EMckCre− /−
mice injected with insulin (Figure 3E), perfusion of rat hearts
with insulin led to an increase in SGK3 Thr320 activation
loop phosphorylation (Figure 6B). However, the insulin-induced
increase in SGK3 Thr320 phosphorylation was unaffected by pre-
treatment with Akti-1/2 (Figure 6B).
Effect of insulin on heart PFK-2 activation in HEK-293T cells
co-transfected with PKB siRNAs
HEK-293T cells were co-transfected with a vector coding for
His6-tagged recombinant BH PFK-2 [23] and either control
siRNA or PKBα/β siRNA, to knockdown the expression
of both PKB isoforms. Immunoblotting with the anti-total
PH-domain PKB antibody indicated that the PKBα/β siRNA
treatment decreased the PKB content of the cells by more than
80% without affecting PKCζ expression (used as a loading
control) (Figure 7A). In order to evaluate the efficiency of PKB
Figure 7 Effect of PKBα/β knockdown by siRNA on insulin-induced PFK-2
activation in transfected HEK-293T cells
HEK-293T cells were co-transfected with siRNA vectors (see the Experimental section) as
indicated. (A) Extracts were immunoblotted with anti-total PH-domain PKB and anti-total PKCζ
(loading control) antibodies (a representative blot from two experiments is shown in the lower
panel). Following scanning densitometry, band intensities obtained with the anti-total PKB
antibody were calculated relative to band intensities obtained with the loading control (upper
panel). The cells were serum-starved and incubated with (black bars) or without (white bars)
0.1 μM insulin for 10 min. (B) Extracts were immunoblotted with anti-phospho-Thr389 p70S6K
and anti- PKCζ (loading control) antibodies for quantification of p70S6K phosphorylation relative
to the loading control as described for (A) (a representative blot is shown). (C) PFK-2 activities
were measured in cell extracts under V max conditions and expressed as arbitrary units, after
correction for PFK-2 expression levels, by immunoblotting as described in the Experimental
section. The results are the means +− S.E.M. for three separate experiments. *P < 0.05 for the
effect of insulin compared with the control (paired t test). ∗∗P < 0.05 for the effect of insulin in
cells transfected with PKB siRNA compared with cells transfected with control siRNA (paired t
test).
knockdown, the phosphorylation state of Thr389 of p70S6K, an
indirect downstream target, was measured by immunoblotting.
In cells treated with control siRNA, insulin increased p70S6K
Thr389 phosphorylation by approx. 50%, which was completely
abrogated by transfection with PKBα/β siRNA (Figure 7B).
Moreover, in PKBα/β siRNA-treated HEK-293T cells, heart
PFK-2 activation by insulin was likewise abolished (Figure 7C).
The results suggest that PKBα and/or PKBβ is involved in insulin-
induced heart PFK-2 activation.
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In HEK-293T cells co-transfected with His6-tagged BH PFK-
2 and PKBα siRNA, a PKBα knockdown of at least 50% was
achieved after 96 h of transfection (Supplementary Figure S2A at
http://www.BiochemJ.org/bj/431/bj4310267add.htm); however,
the anti-PKBα antibody used for immunoblotting was not totally
specific and cross-reacts to some extent with PKBβ. Total
PKB expression was unchanged (Supplementary Figure S2A)
and there was no effect of PKBα knockdown on PKB Ser473
phosphorylation (Supplementary Figure S2B). In addition, by
immunoblotting with the specific antibodies, we were unable to
detect any change in expression of PKBβ or PKBγ following
PKBα knockdown (results not shown). The 96 h time frame
of transfection needed to achieve a reasonable knockdown in
the PKBα expression resulted in a large overexpression of co-
transfected PFK-2, such that no or little effect of insulin treatment
on PFK-2 activity was evident. Therefore we resorted to the use
of the anti-PAS antibody to monitor PFK-2 phosphorylation in
response to insulin. PKBα siRNA transfection abrogated insulin-
induced PFK-2 phosphorylation (Supplementary Figure S2C),
thus implicating this PKB isoenzyme in heart PFK-2 activation
by insulin.
DISCUSSION
In a classic review of reversible phosphorylation of enzymes,
Krebs and Beavo [40] proposed a set of criteria for
establishing that changes in enzyme activity as a result of
phosphorylation/dephosphorylation by a protein kinase would
be physiologically relevant. The third and fourth criteria, which
are the most difficult to satisfy, state that the enzyme should
be shown to be phosphorylated/dephosphorylated in vivo or in
an intact cell system with accompanying functional changes
and that there should be a correlation between cellular levels
of protein kinase effectors and the extent of phosphorylation
of the enzyme respectively. When Krebs and Beavo [40]
proposed their criteria for establishing physiologically relevant
phosphorylation/dephosphorylation of enzymes, this was mainly
based on the study of protein phosphorylation in response to
changes in cAMP. To verify that a particular protein kinase is the
physiologically relevant kinase for a target enzyme in stimulated
cells, changes in cellular kinase activity should be correlated with
a change in activity of the target enzyme. Nowadays this can be
done either by incubating cells with selective kinase inhibitors, by
transfecting cells with vectors overexpressing constitutively active
and/or dominant-negative forms of the kinase, by knockdown of
the kinase by transfecting siRNAs, or by using mouse knockout
or transgenic models.
In the present study we showed that, in HEK-293T cells, insulin
activated SGK3 and that treatment of heart PFK-2 with SGK3 in
vitro led to PFK-2 activation and phosphorylation at Ser466 and
Ser483, the same sites phosphorylated by PKB in vitro. As cultured
cardiomyocytes cannot be easily transfected, we investigated
the role of SGK3 in insulin-induced heart PFK-2 activation in
transfected HEK-293T cells. Co-transfection of HEK-293T cells
with SGK3 siRNA indicated that SGK3 was not required for
insulin-induced heart PFK-2 activation, a conclusion supported
by studies on heart PFK-2 activation by insulin in the PDK1 PIF-
pocket mutation knockin mice and use of the Akti-1/2 selective
PKB inhibitor (see below). Our previous conclusions that PKB
was not involved in heart PFK-2 activation by insulin were based
on experiments using a dominant-negative PKB construct in co-
transfection experiments in HEK-293 cells [23], which led us to
embark on the purification of WISK [25]. However, the dominant-
negative approach has inherent drawbacks, such as incomplete
competition with endogenous PKB, lack of sequestration of
PKB in the right intracellular compartment and the fact that the
dominant-negative PKB might not titrate out the relevant PKB
isoenzyme to completely block insulin-induced PFK-2 activation.
Clearly, in order to verify the last of the Krebs and Beavo
criteria, as many different approaches as possible for correlating
intracellular kinase activity with the biological response should
be tested before definitive conclusions are drawn. Therefore we
re-evaluated the role of PKB by studying PFK-2 activation by
insulin in different models, namely hearts from transgenic mice,
cardiomyocytes and perfused hearts treated with Akti-1/2 PKB
inhibitor, and HEK-293T cells after PKB knockdown by siRNA.
The fact that insulin-induced heart PFK-2 activation was still
observed in conditional knockin mice bearing a mutation in the
PDK1 substrate-binding motif (Figures 3C and 3D) argues against
the involvement of kinases other than PKB (those containing a
hydrophobic phosphorylation site motif but without a PH domain)
for insulin-induced PFK-2 activation. Indeed, the increase in
SGK3 activation loop Thr320 phosphorylation induced by insulin
injection in control mice was abolished in the PDK1 PIF-pocket
knockin mice (Figure 3E). In freshly isolated rat cardiomyocytes
incubated with the Akti-1/2 inhibitor, PFK-2 activation by insulin
was almost ablated (Figure 5D) and in hearts perfused with Akti-
1/2 insulin-induced PKB activation markedly decreased, whereas
the increase in SGK3 Thr320 phosphorylation was unaffected
(Figure 6). Thus, whereas the PDK1 PIF-pocket knockin mouse
model can differentiate between insulin effects on PKB activity
and SGK3 Thr320 phosphorylation in vivo (Figure 3), the use
of Akti-1/2 in perfused hearts can distinguish between PKB
activation and SGK3 Thr320 phosphorylation by insulin ex vivo
(Figure 6). Experiments in HEK-293T cells after PKBα/β siRNA
knockdown clearly implicated either PKBα or PKBβ in heart
PFK-2 activation by insulin (Figure 7). Unexpectedly, in hearts
from PKBβ-deficient mice, insulin-induced PFK-2 activation was
not abolished and was even greater than in wild-type mice,
presumably due to overcompensation by PKBα in hearts of the
knockout animals (Figure 4). Hence, we conclude that PKBβ
does not mediate heart PFK-2 activation by insulin, which we
propose rather involves PKBα, as supported by the fact that siRNA
knockdown of this PKB isoenzyme in HEK-293T cells ablated
heart PFK-2 phosphorylation (Supplementary Figure S2).
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Figure S1 Effect of insulin on GST–SGK3 activation and phosphorylation in
transfected HEK-293T cells
HEK-293T cells expressing the wild-type SGK3 GST-fusion construct were treated with
0.1 μM insulin for the indicated times. GST–SGK3 activity was measured in extracts after
immunoprecipitation and extracts were immunoblotted with anti-phospho-Thr320 SGK3 and
anti-total SGK3 antibodies as a loading control (a representative blot is shown in the lower
panel). Following scanning densitometry, band intensities obtained with anti-phospho-Thr320
SGK3 antibody were calculated relative to band intensities for the loading control (upper panel).
The results are means +− S.E.M. for three separate experiments. *P < 0.05 for the effect of
insulin compared with the controls (paired t test).
1 These authors contributed equally to this work.
2 To whom correspondence should be addressed (email mark.rider@uclouvain.be).
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Figure S2 Effect of PKBα knockdown by siRNA on insulin-induced PFK-2
activation in transfected HEK-293T cells
HEK-293T cells were co-transfected with siRNA vectors (see the Experimental section in the main
paper) as indicated. (A) Extracts were immunoblotted with the anti-PKBα, anti-total PH-domain
PKB and anti-β-actin (loading control) antibodies (a representative blot from two experiments is
shown in the lower panel). Following scanning densitometry, band intensities obtained with the
anti-total PKBα antibody were calculated relative to band intensities obtained with the loading
control (upper panel). The cells were serum-starved and incubated with (black bars) or without
(white bars) 0.1 μM insulin for 10 min. (B) Extracts were immunoblotted with anti-phospho
Ser473 and anti-β-actin (loading control) antibodies for quantification of PKB phosphorylation
as described for (A) (a representative blot is shown below the histogram). (C) Extracts were
immunoblotted with anti-PAS and anti-full-length heart PFK-2 (loading control) antibodies
for quantification of heart PFK-2 phosphorylation as described above (a representative blot is
shown below the histogram). The results are the means +− S.E.M. for three separate experiments.
*P < 0.05 for the effect of insulin compared with the control (paired t test). **P < 0.05 for
the effect of insulin in cells transfected with PKBα siRNA compared with cells transfected with
control siRNA (paired t test).
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